A neomorphic protein interface catalyzes covalent inhibition of RAS <sup>G12D</sup> aspartic acid in tumorsCaroline E. Weller, David Wildes, G. Leslie Burnett et al.|Science|2025Cited by 31
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaUrszula N. Wasko, Kenneth P. Olive, Jingjing Jiang et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 11
Mechanisms of resistance to active state selective tri-complex RAS inhibitorsBen Sang, Piro Lito, Ignacio Garrido‐Laguna et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 10
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMallika Singh, David Wildes, Matthew Holderfield et al.|Research Square|2023Cited by 5
Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination StrategiesIda Aronchik, Mallika Singh, Sumit Kar et al.|Molecular Cancer Therapeutics|2025Cited by 1